Skip to main content
Equibles

CRDL · Cardiol Therapeutics Inc. · Documents

Use CRDL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRDL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1.4100 CAD +0.0800 (+6.02%) At close · Nov 6 Intraday price with Plus
Rebalance outlook locked

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Annual report FY2025 Net loss 33.82M CAD 40-F filed Mar 31, 2026
2026
Nov 3
Current report 6-K
US$75,000,000 common share sale agreement

Cardiol Therapeutics Inc. agreed with Jefferies LLC to issue and sell common shares with an aggregate offering price of up to US$75,000,000.

Read from the first part of this long document
Source passage
Cardiol Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”) to issue and sell common shares of the Company (the “Common Shares”) having an aggregate offering price of up to US$75,000,000 (the “Shares”) upon and subject to the terms and conditions contained herein. Open the document at this passage
Nov 3
Current report 6-K
US$75 million ATM equity program launched

Cardiol Therapeutics Inc. entered an agreement with Jefferies LLC to offer and sell up to US$75 million under an at-the-market program. The company has no obligation to sell any shares, and proceeds would support CardiolRx and CRD-38 development.

4 source passages
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales Agent") for an at-the-market offering program (the "ATM Program"). The ATM Agreement will allow the Company to offer and sell up to US$75 million of common shares of the Company (the "Offered Shares") under the ATM Program. The timing and extent of the use of the ATM Program will be at the discretion of the Company, and the Company has no obligation to sell any shares pursuant to the ATM Program. As outlined in the Supplement, the Company intends to use the net proceeds of any such sales under the ATM Program to support the development of CardiolRx™ for the treatment of recurrent pericarditis including, subject to the Phase III MAVERIC trial outcomes, supporting a New Drug Application, to support the clinical development of CRD-38 and for general and administrative expenses, working capital and other expenses. Open the document at this passage
Nov 3
Offering documents SEDAR+
4 offering documents
  • Auditors' consent letter 1
  • Other material contract(s) 1
  • Shelf prospectus (NI 44-102) 1
  • Consent letter of issuer's legal counsel 1
Sep 23
Current report 6-K
Current report

Cardiol Therapeutics Inc. reached 110-patient MAVERIC enrollment target ahead of schedule and plans expansion to up to 150 patients after fewer-than-expected recurrences. Topline results are anticipated in mid-2027, versus previous Q1 2027 guidance; cash runway extends into Q1 2028.

Sep 16 to Sep 10
Offering documents SEDAR+
18 offering documents
  • Non-issuer's submission to jurisdiction and appointment of agent 5
  • Shelf prospectus (NI 44-102) 3
  • Consent letter of issuer's legal counsel 2
  • Auditors' consent letter 2
  • Other offering documents 6
Aug 12
Report SEDAR+
MD&A
Showing 1–50 of 525 documents